Skip to content
Kalpvruksh Markets
Offline Log in

GLAXONSEOffline

GLAXOSMITHKLINE PHAR · INE159A01016 · Mid Cap · #226
2,500.20−31.60 (−1.25%)last close · 05 Nov 2026
Prev close
2,531.80
Open
—
High
—
Low
—
Volume
—
Mkt cap (6-mo avg)
₹40,592 cr
52-week range · to 05 Nov 20262,103.23,106.4

Loading minute bars…

NSE 1-minute bars from our CandleApi gateway (history from 21 Jul 2026); longer timeframes are built from them. Prices not adjusted for corporate actions.

GLAXO is 20% below its 52-week high, below its 200-day average, behind Healthcare by 3.6 pts over 3 months — a Mid Cap company, #226 by market cap.NSE prices to 05 Nov 2026 · a description of the data, not advice

Overview

What the data says, line by line

A description, never a buy or sell word · tap a line for its detail

  • below its 20 / 50 / 200-day averages · 20% below its 52-week high
  • behind its industry by 3.6 pts over 3 months · rank 29 of 44 in Healthcare · −0.6% vs Nifty 500
  • traded value 1.7× usual · delivery 59% vs 53% usual
  • FPI −0.0 pp · DII +0.7 pp · MF schemes in Sept 2026: 41 bought, 38 cut · no promoter pledge · quarter ended 2026-09-30
  • Jun 2026 quarter: profit +16% year on year · revenue +17%
  • nothing scheduled or restricting

How big is it?

six-month average market cap

Market capitalisation
₹40,592 cr
Rank
#226
Cap band
Mid Cap
Nearest cut-off — Mid / Small
+18.72% from ₹34,190 cr
Clear of the cut-off

Our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page.

Did buyers take delivery?

latest session · 2026-11-05

vs its own normal
4.0×
median 27,749
Delivered
1,10,911
Of volume
72%

Price & trend

Returns

to 05 Nov 2026

PeriodStockvs Nifty 500vs its industry
1 week−0.6%−6.1 pts—
1 month−9.2%−13.2 pts−12.7 pts
3 months−2.7%−0.6 pts−3.6 pts
6 months+3.2%+2.8 pts−7.0 pts
1 year−4.6%−2.1 pts—

Industry: Healthcare (Nifty 500 classification) · rank 29 of 44 over 3 months. Points = the stock’s return minus the benchmark’s. Prices adjusted for splits and bonuses.

Averages & movement

vs 20-day average
−0.3%
below
vs 50-day average
−8.5%
below
vs 200-day average
−0.6%
below
ATR (14)
2.9%
typical daily range
Volatility
26%
1 month, annualised
Beta
0.56
vs Nifty 500, 1 year
Traded value
1.7×
vs usual
Delivery
59%
usual 53%
From the 52-week high
−19.5%
place in range 40% (0 = at the low)

Ownership

Who owns the company

% of all shares, by quarter

GroupDec 25Mar 26Jun 26Sep 26
Promoters75.0%75.0%75.0%75.0%
FPI4.6%4.6%4.8% +0.24.8%
Mutual funds4.8%4.7%4.9% +0.16.1% +1.2
Other DII2.9%3.0%2.9%2.4% −0.5
Individuals10.4%10.3%10.2% −0.19.7% −0.6
Others2.3%2.4%2.2% −0.22.1% −0.1

From the company’s quarterly shareholding pattern. Changes in percentage points against the quarter before. No quarters are on record between Sep 2022 and Jun 2025.

Promoter pledge

Sep 26

Of promoters’ holding
none
Of all shares
none
Jun 25 noneSep 25 noneDec 25 noneMar 26 noneJun 26 noneSep 26 none

Holders

Sep 26

All shareholders
1,19,337
Individuals
1,11,806

Indian passive funds’ stake

2026-06-30

Of free float
0.73%
Of all shares
0.18%
Schemes
68
Days to unwind
3.8
at 100% of volume

3,10,462 shares held by Indian passive mutual-fund schemes. A floor, not the total — foreign ETFs, insurance and EPFO are not counted.

Which funds bought and sold

mutual funds · quarter ended 2026-06-30

Funds holding
121
68 index · 53 active
Bought more
71
Sold some
24
FundSharesChangeDid
Tata Aggressive Hybrid Fund-Reg(G)Active+3,00,000+2000.0%bought
Helios Mid Cap Fund-Reg(G)Active+77,000+372.2%bought
Helios Large & Mid Cap Fund-Reg(G)Active+42,040+323.9%bought
Mahindra Manulife Small Cap Fund-Reg(G)Active−1,29,760−70.9%sold
Aditya Birla SL Multi-Cap Fund-Reg(G)Active−1,26,292−55.8%sold
Tata Retirement Sav Fund - Mod Plan(G)Active−37,030−52.0%sold

Ranked by how much each fund changed its own position, not by size of trade. Every fund here still holds the company — one that sold out entirely leaves no record to find.

Mutual-fund schemes, month by month

fund houses’ own monthly portfolios

MonthSchemesBought newAddedCutSold outShares heldValue
Sep 26114536362+2.9%₹2,077 cr
Aug 261111461125+11.8%₹2,223 cr
Jul 26102343270+7.4%₹1,731 cr
Jun 2699752203+10.5%₹1,488 cr
May 2695344171+2.7%₹1,215 cr
Apr 2693250101−1.6%₹1,250 cr

Each month against the one before, counting only the fund houses that reported both (45 houses in Sep 26); a split or bonus is divided out first. “Partial” = fewer than five houses reported yet.

Fund ownership is a quarterly disclosure and counts Indian passive schemes only.

Results

Results

Events & filings

Disclosures & deals

last six months · NSE filings

  • Board outcome
    GlaxoSmithKline Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
    04 Nov 2026
  • Board outcome
    GlaxoSmithKline Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
    03 Aug 2026

GLAXO: only ratings, pledges, insider and takeover disclosures, buybacks, schemes, board outcomes and deals are listed. All deals.

Corporate actions

full published history

0 selected
EarlierDividend₹57Final29 May 202629 May 2026
EarlierDividend₹42Final30 May 202530 May 2025
EarlierDividend₹12Interim07 Nov 202407 Nov 2024
EarlierDividend₹32Final31 May 202431 May 2024
EarlierDividend₹32Final30 Jun 202330 Jun 2023
EarlierDividend₹60Special07 Jul 202208 Jul 2022
EarlierDividend₹30Final07 Jul 202208 Jul 2022
EarlierBonus1:1—11 Sept 201813 Sept 2018

8 shown. A falling price on an ex-date is not a loss: a dividend leaves the share as cash and a bonus multiplies the shares held.

Market capitalisation is our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page. Fund ownership is a quarterly disclosure and counts Indian passive schemes only. Nothing here is advice, a recommendation, or a view on the company.